PDS Biotechnology (PDSB)

• Market cap: $49M
• 1 day: 3.85%
• 5 days: 12.50%
• 1 month: -19.40%
• 3 months: -25.52%
• 6 months: -65.16%
• Year to date: -37.57%
• 1 year: -60.29%
• 5 years: 8.59%
• 10 years: -91.65%
• Sector: Healthcare
• Industry: Biotechnology

About: PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Employees: 24

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,108% more call options, than puts

Call options by funds: $157K | Put options by funds: $13K

7% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 15

0.42% less ownership

Funds ownership: 11.75% [Q3] → 11.33% (-0.42%) [Q4]

9% less funds holding

Funds holding: 56 [Q3] → 51 (-5) [Q4]

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

58% less capital invested

Capital invested by funds: $16.5M [Q3] → $6.92M (-$9.59M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $13 1,104% upside
• Avg. target: $13 1,104% upside
• High target: $13 1,104% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target

1,104% upside $13

Buy Maintained

27 Mar 2025